NCT05083143

Brief Summary

In this study, investigators aim to reveal how the COVID-19 pandemic process affects testicular cancer presentations, tumor stages, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2021

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 17, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 19, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2022

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 25, 2022

Completed
Last Updated

April 27, 2022

Status Verified

April 1, 2022

Enrollment Period

9 months

First QC Date

October 17, 2021

Last Update Submit

April 20, 2022

Conditions

Testicular CancerCOVID-19

Keywords

Testicular CancerCOVID-19Radical Orchiectomy

Outcome Measures

Primary Outcomes (1)

  • Rate of tumor stages

    Rate of tumor stages in patients who diagnosed with testicular cancer

    2 month

Study Arms (2)

COVID-19 Testicular Cancer

Patients diagnosed with testicular cancer in the COVID-19 period

Behavioral: COVID-19 pandemic

PreCOVID-19 Testicular Cancer

Patients diagnosed with testicular cancer before the COVID-19 period

Behavioral: COVID-19 pandemic

Interventions

COVID-19 pandemicBEHAVIORAL

Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.

COVID-19 Testicular CancerPreCOVID-19 Testicular Cancer

Eligibility Criteria

Age18 Years - 65 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients diagnosed with testicular cancer in the urology clinic

You may qualify if:

  • Patients diagnosed with testicular cancer in the urology clinic.

You may not qualify if:

  • Previous history of genitourinary system tumor
  • Previous history of radiotherapy or chemotherapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Training and Research Hospital

Ankara, Altindag, 06230, Turkey (Türkiye)

Location

Related Publications (3)

  • Yue H, Bai X, Wang J, Yu Q, Liu W, Pu J, Wang X, Hu J, Xu D, Li X, Kang N, Li L, Lu W, Feng T, Ding L, Li X, Qi X; Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. Ann Palliat Med. 2020 Jul;9(4):1404-1412. doi: 10.21037/apm-20-887. Epub 2020 Jul 13.

    PMID: 32692208BACKGROUND

  • Moul JW, Paulson DF, Dodge RK, Walther PJ. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol. 1990 Mar;143(3):520-3. doi: 10.1016/s0022-5347(17)40007-3.

    PMID: 2304163BACKGROUND

  • Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul;78(1):29-42. doi: 10.1016/j.eururo.2020.04.063. Epub 2020 May 3.

    PMID: 32414626BACKGROUND

MeSH Terms

Conditions

Testicular NeoplasmsCOVID-19

Interventions

Pandemic Preparedness

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesEndocrine System DiseasesTesticular DiseasesGonadal DisordersPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Disaster PlanningDisastersEnvironmentEnvironment and Public HealthCommunicable Disease ControlPublic Health PracticePublic Health

Study Officials

  • Ali Kaan Yıldız

    Ankara Training and Resarch Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 17, 2021

First Posted

October 19, 2021

Study Start

July 1, 2021

Primary Completion

March 15, 2022

Study Completion

March 25, 2022

Last Updated

April 27, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations

TU(1)